Glenmark Pharmaceuticals

GLENMARK.NS

Mumbai, India· Est. 1977

glenmarkpharma.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

GLENMARK.NS · Stock Price

INR 2,371.60+973.40 (+69.62%)

Market Cap: $7.1B

Historical price data

Market Cap: $7.1BPipeline: 25 drugs (9 Phase 3)Founded: 1977Employees: 16,000+HQ: Mumbai, India

Sector Ranking#18 in Small Molecule Drugs #11 in Biologics / Biosimilars

Overview

Glenmark Pharmaceuticals has evolved from its 1977 founding into a diversified, global pharmaceutical enterprise with a strategic focus on innovation and accessibility. Under the leadership of Chairman & Managing Director Glenn Saldanha, the company has built significant capabilities in R&D, biologics, and complex generics, supported by a robust pipeline of 25+ candidates and a global commercial footprint. Its strategy centers on advancing a focused pipeline in respiratory, dermatology, and oncology through its biotech arm Ichnos Glenmark Innovation (IGI), while simultaneously scaling its generics and branded formulations business across emerging and developed markets.

DermatologyRespiratoryOncology

Technology Platform

A vertically integrated platform encompassing advanced API synthesis, complex formulation development, and a full-spectrum biologics engine for novel antibodies and biosimilars via Ichnos Glenmark Innovation (IGI).

Pipeline

25 drugs in pipeline9 in Phase 3

Drug	Indication	Stage
Nitric Oxide	SARS-CoV-2 Infection	Phase 3
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT H...	Bronchial Asthma	Phase 3
Diclofenac Sodium gel, 1% + Voltaren® Gel + Placebo	Osteoarthritis	Phase 3
Calcipotriene/ betamethasone dipropionate topical foam, 0.00...	Psoriasis Vulgaris	Phase 3
Calcipotriene/Betamethasone Dipropionate + Taclonex® + Place...	Scalp Psoriasis	Phase 3

Funding History

IPOUndisclosedUndisclosedJun 15, 1999

FDA Approved Drugs

FLUTICASONE PROPIONATEANDAMar 16, 2026

POTASSIUM PHOSPHATESANDAMar 12, 2026

FLUTICASONE PROPIONATEANDAMar 3, 2026

Opportunities

Glenmark is poised to capitalize on the growing global demand for biosimilars and complex generics, particularly in respiratory and dermatology.

Its focused innovation in oncology and immunology through IGI targets high-value segments with significant unmet medical need, offering substantial upside potential.

Risk Factors

Key risks include clinical failure or delays in its novel pipeline, intense pricing pressure and regulatory challenges in the generics business, and the operational complexity of managing a globally diversified hybrid business model.

Competitive Landscape

Glenmark competes with large Indian generics firms (Sun Pharma, Dr. Reddy's) and global generics players in its core business, while its innovation arm faces competition from global biopharma and biotech companies. Its differentiation lies in cost-efficient R&D, vertical integration, and a strategic focus on complex therapy areas.